Luo Ruihong, Greenberg Alan, Stone Christian D
*Department of Internal Medicine ‡Section of Gastroenterology and Hepatology, University of Nevada School of Medicine †Infectious Disease Specialists, University Medical Center of Southern Nevada, Las Vegas, NV.
J Clin Gastroenterol. 2015 Aug;49(7):620-7. doi: 10.1097/MCG.0000000000000216.
Patients with hepatitis C virus infection often require hospitalization for progressive liver disease and complications, incurring high cost and risk of death.
The aim of our study was to investigate recent trends in the economic burden and outcomes of patients hospitalized for hepatitis C in the United States.
Patients with hepatitis C-associated hospitalization were identified from the Nationwide Inpatient Sample 2005 to 2011. We analyzed the in-hospital mortality, hospital service utilization, demographic, and clinical features of patients. A prognostic model to predict in-hospital survival and death with independent risk factors for mortality was developed.
A total of 607,279 cases of hepatitis C-associated hospitalization were identified. Over 7 years, the annual hospitalized volume increased by 28.8%. In-hospital mortality declined from 8.2% to 6.4%. Median length of stay (4 d) was unchanged but the inflation-adjusted hospital charges increased by 33.3%. Acute respiratory failure was the greatest independent risk factor for mortality [odds ratio (OR)=7.3; 95% confidence interval (CI), 7.0-7.5], followed by septicemia (OR=4.1; 95% CI, 4.0-4.3), renal failure (OR=3.4; 95% CI, 3.3-3.5), and acute liver failure (OR=2.9; 95% CI, 2.7-3.0). On the basis of the major risk factors for mortality, a risk-adjusted model was developed that could predict the in-hospital outcome of hepatitis C patients with an accurate rate of 89.2%.
Despite decreasing in-hospital mortality, both hospital volume and charges related to hepatitis C increased from 2005 to 2011. Use of a risk-adjusted model could help predict mortality and improve outcomes of hepatitis C inpatients.
丙型肝炎病毒感染患者常因进行性肝病及并发症而需住院治疗,这会带来高昂费用及死亡风险。
我们研究的目的是调查美国丙型肝炎住院患者经济负担及治疗结果的近期趋势。
从2005年至2011年的全国住院患者样本中识别出丙型肝炎相关住院患者。我们分析了患者的院内死亡率、医院服务利用情况、人口统计学特征及临床特征。开发了一种预测院内生存和死亡的预后模型,该模型包含死亡率的独立危险因素。
共识别出607279例丙型肝炎相关住院病例。在7年期间,年度住院量增加了28.8%。院内死亡率从8.2%降至6.4%。中位住院时间(4天)未变,但经通胀调整后的医院收费增加了33.3%。急性呼吸衰竭是死亡率的最大独立危险因素[比值比(OR)=7.3;95%置信区间(CI),7.0 - 7.5],其次是败血症(OR = 4.1;95% CI,4.0 - 4.3)、肾衰竭(OR = 3.4;95% CI,3.3 - 3.5)和急性肝衰竭(OR = 2.9;95% CI,2.7 - 3.0)。基于死亡率的主要危险因素,开发了一种风险调整模型,该模型能够以89.2%的准确率预测丙型肝炎患者的院内治疗结果。
尽管院内死亡率有所下降,但2005年至2011年期间,与丙型肝炎相关的住院量和费用均有所增加。使用风险调整模型有助于预测死亡率并改善丙型肝炎住院患者的治疗结果。